Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02777476
Other study ID # CL-010
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date December 2028

Study information

Verified date September 2023
Source G&G Biotechnology Ltd.
Contact Dael Govreen-Segal
Email info@gg-bio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a post-marketing study for B-Lite® implants that carry the EC certificate for marketing in Europe and AMAR certificate for marketing in Israel. To date, thousands of implants have already been implanted in women. The study is open for primary augmentation patients only. All surgeries will be performed as per standard practice at the given study site. No parallel surgical procedures will be performed at the same session.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 2028
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Genetic women between the ages of 18 and 60 seeking primary breast augmentation - Patient is eligible to undergo MRI (i.e., no implanted metal or metal devices, no history of severe claustrophobia) - Patient provides signed informed consent - Patient agrees to comply with the study protocol and complete all required follow up visits, including to undergo MRI - Patient agrees to return the device to the Sponsor should the implant have to be explanted - The patient has realistic expectations of surgical results after discussion with investigator and is an acceptable candidate for breast augmentation. Exclusion Criteria: - Patients with active infection anywhere in their body - Patient is pregnant or nursing at the time of recruitment, or has been in the 6 months preceding recruitment date, or not willing to use reliable means of contraception during the first year after surgery - Patient was implanted with any silicone implant other than breast implants (e.g., silicone artificial joints or facial implants) - Patient breast tissue is clinically incompatible for the procedure (e.g., tissue damage resulting from radiation, insufficient tissue coverage or compromised vascularity) - Patient has a condition, or is under treatment for any condition, which, in the opinion of the investigator and/or consulting physician(s), may constitute an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems, possible allergies and/or extraordinary immune response to implant) - The patient has a history of mental instability and/or history of pharmaceutical psychiatric treatment - Patient unable to understand the scope of the study and/or surgery - The patient has any disease, including uncontrolled diabetes (e.g., HbA1c > 8%), that is clinically known to impact wound healing ability - Patient has existing costal injuries - Patient has abscesses, malignant tumors (cancer or recurrent metastases), clinically relevant cysts or advanced fibrotic disease or patient with BIRAD =3 - Are not willing to undergo further surgery for revision, if medically required - The patient has a confirmed rheumatic disease or syndrome (e.g., SLE, Sjogren's syndrome, scleroderma, polymyositis or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia or chronic fatigue syndrome) - The patient has a severe breast and upper trunk deformity - The patient participated in an investigational trial within 90 days of enrollment - The patient has undergone an invasive medical procedure within 90 days of enrollment. - Aesthetic addiction, drug abuse, alcohol abuse

Study Design


Related Conditions & MeSH terms


Intervention

Device:
B-Lite- Light Weight Breast Implants


Locations

Country Name City State
Germany ETHIANUM Heidelberg
Israel Herzelia Medical Center Herzliya
Sweden Akademikliniken Stockholm
Switzerland Concept-Clinic Geneva
United Kingdom London Bridge Plastic Surgery Ltd London

Sponsors (1)

Lead Sponsor Collaborator
G&G Biotechnology Ltd.

Countries where clinical trial is conducted

Germany,  Israel,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in breast size measurements 3 years
Primary Changes in bra size measurements 3 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06013514 - Post-market Prospective Clinical Study of Nagor Perle Mammary Implants
Withdrawn NCT01857765 - Breast Augmentation Rehabilitation Program N/A
Recruiting NCT06147661 - Primary Aesthetic Breast Augmentation: Comparative Study Between Breast Implants and Autograft of Adipose Tissue
Completed NCT00858052 - Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants N/A
Completed NCT01874652 - Assessment of Safety & Efficacy of Light Weight Breast Implant Phase 2
Active, not recruiting NCT03579901 - Study of the Safety and Effectiveness of Motiva Implants® N/A